Lupin Limited
http://www.lupin.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lupin Limited
Indian Leaders Climb Into Generics And Biosimilars Top 10
In a year that has seen significant changes throughout the generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders. Meanwhile, companies lower down our ranking have enjoyed mixed fortunes, leading to a number of significant movements in this year’s Generics Bulletin Top 50.
Astellas India MD On Action-Packed Run Ahead, Breaking The Glass Ceiling
In an interview with Scrip, Astellas’s India chief outlines how the Japanese company expects to build out its operations in the country, with a flurry of key launches in the wings. She also shares vignettes of her own career path, which has not been a bed of roses.
Lupin Looks To Be First Out Of The Blocks On US Ingrezza, With Zydus Second
ANDA sponsors targeting Neurocrine Biosciences’ Ingrezza (valbenazine) blockbuster are in position to launch – albeit with a 14-year wait that validates the strength of the originator’s IP.
Generic Spiriva Delivers First Mover Advantage In US, Lupin Plans Europe Launch
Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Nutraceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Pulmonary
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Generic Health Pty Ltd
- Temmler Pharma GmbH & Co.
- YL Biologics (YLB)
- ZAO Biocom
- Kyowa Pharmaceutical Industry Co., Ltd.
- Southern Cross Pharma Pty Ltd
- Symbiomix Therapeutics, LLC.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice